During tumor evolution, cancer cells can acquire the ability to proliferate, invade neighboring
tissues, evade the immune system, and spread systemically. Tracking this process remains …

For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …

In lung adenocarcinoma, oncogenic EGFR mutations co-occur with many tumor suppressor
gene alterations; however, the extent to which these contribute to tumor growth and …

Building a genotype-phenotype-fitness map of adaptation is a central goal in evolutionary
biology. It is difficult even when adaptive mutations are known because it is hard to …

Experimental preclinical models have been a cornerstone of lung cancer translational
research. Work in these model systems has provided insights into the biology of lung cancer …

Cancer genotyping has identified a large number of putative tumor suppressor genes.
Carcinogenesis is a multistep process, but the importance and specific roles of many of …

Tumors acquire alterations in oncogenes and tumor suppressor genes in an adaptive walk
through the fitness landscape of tumorigenesis. However, the interactions between …

Small cell lung cancer (SCLC) is a lethal form of lung cancer. Here, we develop a
quantitative multiplexed approach on the basis of lentiviral barcoding with somatic CRISPR …

Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only
some of which drive oncogenesis at certain times during cancer evolution. Identifying the …

Cancer genomes are almost invariably complex with genomic alterations cooperating during
each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation …